Checkpoint inhibitors for the programmed cell death protein 1 (PD-1/PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) pathways have been developed for the treatment of cancer. The gene discussed is CTLA4; the disease is cancer.